HORIZON-MISS-2026-02-CANCER-01

Virtual Human Twin (VHT) Models for Cancer Research

Status
open for submission
Programme
Horizon Europe (HORIZON)
Action type
HORIZON Research and Innovation Actions
Opens
10 Feb 2026
Deadline
15 Sep 2026
Fetched
15 Jul 2026, 07:18 UTC
Plain-language summary

Develop advanced Virtual Human Twin models to understand cancer onset, progression, and personalize treatments using AI and multimodal data.

This call funds research to create digital models of human health for cancer. Projects should improve understanding of cancer development and help personalize treatments. The focus is on cancers with limited treatment options or unclear biology.

Likely relevant for

  • Cancer researchers
  • Medical AI developers
  • Healthcare professionals
  • Biomedical data scientists
  • Clinical researchers
  • Multidisciplinary research teams

Project signals

Focus on cancers with poor prognosis or rare typesUse of FAIR data and open science principlesIntegration with European research infrastructuresDevelopment of personalized treatment modelsInclusion of clinical validation or studies

What it funds

  • Development of dynamic, multiscale Virtual Human Twin (VHT) models for cancer onset and progression
  • Integration of AI tools for analysis of large, multimodal FAIR datasets
  • Use of augmented/virtual reality for model visualization when appropriate
  • Validation of VHTs with longitudinal patient data for clinical relevance
  • Contribution to open science platforms like UNCAN.eu and Advanced VHT Platform
  • Collaboration across disciplines including healthcare professionals and patients

Expected outcomes

  • Improved mechanistic understanding of cancer onset and progression
  • Enhanced predictive capability of VHTs for personalized cancer treatments
  • Clinical uptake of VHT models demonstrating meaningful observations
  • Availability of data and model assets on open research platforms
  • Strengthened multidisciplinary collaboration in cancer research

Who can apply / participate

  • Research organisations
  • Higher education institutions
  • Healthcare providers
  • SMEs with relevant expertise
  • Industry partners involved in health technology
  • Patient organisations
  • Multidisciplinary consortia encouraged including medical doctors, AI experts, patient representatives, health-IT experts, researchers, SMEs, and EU research infrastructures
  • Eligible countries as per Horizon Europe Annex B
  • Check specific eligibility for non-EU/non-associated countries
  • Compliance with Horizon Europe general and specific conditions
  • Clinical studies require dedicated annex in application
  • Exact consortium size and composition requirements
  • Specific country eligibility for some third countries

Must check before shortlisting

  • Eligibility of participant countries and institutions
  • Capacity to handle large biomedical datasets
  • Ability to collaborate in multidisciplinary consortia
  • Compliance with clinical study annex if applicable

Money

Total indicative budget around €35 million for 2026 with expected grants of 4 projects. Individual grants range from €8 million to €9 million.

  • Total budget for 2026 — 35000000EUR
    Indicative budget for this topic in 2026
  • Expected number of grants — 4
    Four grants expected
  • Minimum grant per project — 8000000EUR
    Minimum funding per grant
  • Maximum grant per project — 9000000EUR
    Maximum funding per grant

Application notes

  • Single-stage submission model.
  • Proposal page limits and layout as per Horizon Europe Work Programme Annexes A and E.
  • Eligibility conditions as per Annex B of Horizon Europe Work Programme.
  • Evaluation criteria thresholds: 4 for Excellence, Impact, and Implementation; cumulative 12.
  • Clinical studies require dedicated annex using provided template.
  • Prepare proposal following Horizon Europe guidelines and templates.
  • Submit proposal via the Funding & Tenders Portal before deadline.
  • Include budget for networking and cluster activities as requested.
  • Ensure multidisciplinary consortium and patient involvement.
  • Address all scope activities and expected outcomes in proposal.
  • Call opening delayed due to technical issues; check portal for updates.
  • Collaboration with other Horizon Europe projects encouraged.
  • Compliance with legal and financial set-up as per Horizon Europe rules.

Derived from official EU Funding portal source · updated 2 Jul 2026, 10:57 UTC. Use this as a shortlisting aid; the official call text remains authoritative.

Related calls

These funding calls are closely related and may be worth considering as part of the same funding landscape.

Official source text

Fine print from the EU source record. Expand when you need the original wording.

Topic description

Expected Outcome: Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to all of the following expected outcomes: Researchers of different disciplines use advanced multiscale Virtual Human Twins (VHTs) to expand the knowledge and understanding of cancer onset and progression Healthcare professionals and researchers have access to advanced VHT-based solutions that model cancer onset and progression over time, contributing to improve personalised treatments Researchers, healthcare professionals, innovators and citizens have access to cancer VHTs through the UNCAN.eu and the advanced Virtual Human Twin platforms Scope: Virtual human twins (VHTs) are digital representations and in-silico models of an individual’s health and disease at different levels of the human anatomy (e.g. cells, tissues, organs or organ systems) for the prevention, prediction, screening, diagnosis and treatment of a disease, as well as the selection and personalisation of intervention options [1] . The proposed topic will contribute to the EU Cancer Mission objectives by improving the accuracy of dynamic and multiscale VHTs to better understand cancer onset, predict progression and develop personalized treatments. Of particular interest for this topic are cancers with limited treatment options or unclear biological mechanisms, refractory cancers, rare cancers, early-onset cancers, cancer types with low five-year survival rates, or paediatric and adolescent cancers [2] . Applicants should take advantage of technological advances in AI tools which open new opportunities to collect, combine and analyse large datasets of diverse types, including multi-omics patient data, tumour molecular profiles, immune profiles, medical images and real word data. Age, sex and gender differences should be duly considered. When relevant, proposals should build on current approaches, standards, data repositories and use modelling assets including but not limited to those provided by the future Advanced VHT Platform [3] , the European Open Science Cloud [4] , the European 1M+ Genomes [5] and the European Cancer Imaging initiatives [6] . The applicants should address all of the following activities: To develop innovative, dynamic multiscale VHTs for advancing the mechanistic knowledge and understanding of cancer onset and progression and develop or improve innovative personalised treatments. VHTs should integrate AI tools for the analysis of large volumes of FAIR (Findable, Accessible, Interoperable, Reusable) multimodal data, increasing their predictive capability and, when appropriate, utilise IT solutions for model visualisation via Augmented Reality/Virtual Reality. To update and validate VHTs with longitudinal newly collected or existing FAIR patient data and generate evidence that VHT models can deliver clinically meaningful observations to improve treatment of the studied cancer type, demonstrating VHT accessibility and usability for clinical uptake. The use of data and services provided by ESFRI research infrastructures in the life science domain [7] should be considered when appropriate. To enrich and make available data and model assets in the UNCAN.eu research platform and in the Advanced VHT Platform following the principles of open science. Newly collected patient datasets must be described with metadata records in the EU dataset catalogue of the European Health Data Space. Collaboration among different scientific disciplines, including healthcare professionals and patients throughout all stages of VHTs development is envisaged [8] . Successful proposals will be asked to join the 'Understanding' project cluster of the EU Cancer Mission [9] and should include a budget for networking, attendance at meetings and joint activities [10] . The Commission will facilitate coordination of this activity. Collaboration is encouraged also with Horizon Europe projects supporting the VHT initiative [11] , as appropriate. Applicants envisaging to include clinical studies should provide details in the dedicated annex using the template provided in the submission system. [1] See the ‘European Virtual Human Twin’ Coordination and Support Action, EDITH, funded under the DIGITAL programme https://www.edith-csa.eu/ [2] Age at first diagnosis 0-19 years [3] https://digital-strategy.ec.europa.eu/en/funding/platform-advanced-virtual-human-twin-vht-models [4] https://research-and-innovation.ec.europa.eu/strategy/strategy-research-and-innovation/our-digital-future/open-science/european-open-science-cloud-eosc_en [5] European '1+ Million Genomes' Initiative | Shaping Europe’s digital future [6] E uropean Cancer Imaging Initiative | Shaping Europe’s digital future [7] https://lifescience-ri.eu/home.html [8] Proposals should include an appropriate mix of stakeholders from various disciplines and sectors, including but not limited to medical doctors, patient representatives, health-IT experts, researchers, AI-experts, solution providers, academia and research institutes, EU research infrastructures, and SMEs [9] In order to address the objectives of the Cancer Mission, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of Cancer Mission R&I and policy actions [10] Examples of those activities are organising joint workshops, establishing best practices, joint communication or citizen engagement activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. Proposals are not required to include details of these activities, as they will be defined during the grant agreement preparation and during the life of the project [11] Including the projects funded under call HORIZON-HLTH-2023-TOOL-05-03, https://hadea.ec.europa.eu/calls-proposals/horizon-europe-health-calls-2023-destination-5-unlocking-full-potential-new-tools-technologies-and_en

Conditions and documents

General conditions

1. Admissibility Conditions: Proposal page limit and layout

described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.

Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.

2. Eligible Countries

described in Annex B of the Work Programme General Annexes.

A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.

3. Other Eligible Conditions

Subject to restrictions for the protection of European communication networks.

described in Annex B of the Work Programme General Annexes.

4. Financial and operational capacity and exclusion

described in Annex C of the Work Programme General Annexes.

5a. Evaluation and award: Award criteria, scoring and thresholds

are described in Annex D of the Work Programme General Annexes.

5b. Evaluation and award: Submission and evaluation processes

The thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.

are described in Annex F of the Work Programme General Annexes and the Online Manual.

5c. Evaluation and award: Indicative timeline for evaluation and grant agreement

described in Annex F of the Work Programme General Annexes.

6. Legal and financial set-up of the grants

The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.

described in Annex G of the Work Programme General Annexes.

Specific conditions

described in the [specific topic of the Work Programme]

Support information

Online Manual is your guide on the procedures from proposal submission to managing your grant. Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe. Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management. Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular. National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’). Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding. IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc. European IPR Helpdesk assists you on intellectual property issues. CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal. The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers. Partner Search help you find a partner organisation for your proposal.

Raw budget overview
{
  "budgetYearsColumns": [
    "2026"
  ],
  "budgetTopicActionMap": {
    "113063": [
      {
        "action": "HORIZON-MISS-2026-02-CANCER-04 - HORIZON-RIA HORIZON  Research and Innovation Actions",
        "expectedGrants": 3,
        "minContribution": 5000000,
        "maxContribution": 5000000,
        "budgetYearMap": {
          "2026": "15000000"
        },
        "plannedOpeningDate": "2026-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2026-09-15"
        ]
      }
    ],
    "113064": [
      {
        "action": "HORIZON-MISS-2026-02-CANCER-01 - HORIZON-RIA HORIZON  Research and Innovation Actions",
        "expectedGrants": 4,
        "minContribution": 8000000,
        "maxContribution": 9000000,
        "budgetYearMap": {
          "2026": "35000000"
        },
        "plannedOpeningDate": "2026-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2026-09-15"
        ]
      }
    ],
    "113065": [
      {
        "action": "HORIZON-MISS-2026-02-CANCER-05 - HORIZON-IA HORIZON Innovation Actions",
        "expectedGrants": 1,
        "minContribution": 7000000,
        "maxContribution": 7000000,
        "budgetYearMap": {
          "2026": "7000000"
        },
        "plannedOpeningDate": "2026-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2026-09-15"
        ]
      }
    ],
    "113066": [
      {
        "action": "HORIZON-MISS-2026-02-CANCER-03 - HORIZON-RIA HORIZON  Research and Innovation Actions",
        "expectedGrants": 3,
        "minContribution": 7000000,
        "maxContribution": 8000000,
        "budgetYearMap": {
          "2026": "22186000"
        },
        "plannedOpeningDate": "2026-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2026-09-15"
        ]
      }
    ],
    "113067": [
      {
        "action": "HORIZON-MISS-2026-02-CANCER-02 - HORIZON-RIA HORIZON  Research and Innovation Actions",
        "expectedGrants": 1,
        "minContribution": 15000000,
        "maxContribution": 15000000,
        "budgetYearMap": {
          "2026": "15000000"
        },
        "plannedOpeningDate": "2026-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2026-09-15"
        ]
      }
    ],
    "113068": [
      {
        "action": "HORIZON-MISS-2026-02-CANCER-06 - HORIZON-CSA HORIZON Coordination and Support Actions",
        "expectedGrants": 1,
        "minContribution": 5000000,
        "maxContribution": 5000000,
        "budgetYearMap": {
          "2026": "5000000"
        },
        "plannedOpeningDate": "2026-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2026-09-15"
        ]
      }
    ],
    "113069": [
      {
        "action": "HORIZON-MISS-2026-02-CANCER-07 - HORIZON-RIA HORIZON  Research and Innovation Actions",
        "expectedGrants": 5,
        "minContribution": 5000000,
        "maxContribution": 6000000,
        "budgetYearMap": {
          "2026": "25000000"
        },
        "plannedOpeningDate": "2026-02-10",
        "deadlineModel": "single-stage",
        "deadlineDates": [
          "2026-09-15"
        ]
      }
    ]
  }
}